title: Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro.
abstract: A panel of 10 digestive tract carcinoma cell lines (6 pancreatic carcinomas) was assayed for their sensitivity to HuLeIFN, human rIFN-gamma, rTNF-alpha and allogeneic human LAK-cells in vitro. In addition, a combination of rIFN-gamma + rTNF-alpha was tested on 3 pancreatic carcinoma cell lines. Whereas 6/7 cell lines were completely resistant to HuLeIFN, rIFN-gamma and rTNF-alpha did inhibit growth of some carcinomas tested. The individual sensitivity was heterogenous as is already known from cytostatics. Response to rIFN-gamma tended to increase with increment of cell doubling time. Only high concentrations (greater than 1000 U/ml) of rIFN-gamma displayed cytotoxicity on sensitive tumors. The antitumoral effect of rIFN-gamma was stimulated by rTNF-alpha. As revealed by isobole analysis this interaction was synergistic in all pancreatic carcinomas tested. In comparison to rIFN-gamma or rTNF-alpha the response to LAK-cells was slightly superior at high effector target ratios, even though heterogenous.
authors.affiliation: Medical Department, University Hospital, Springe, FRG.
authors.forename: J S
authors.initials: JS
authors.lastname: Kühl
authors.forename: R
authors.initials: R
authors.lastname: Klapdor
authors.forename: H
authors.initials: H
authors.lastname: Mohr
authors.forename: H
authors.initials: H
authors.lastname: Arps
authors.forename: M
authors.initials: M
authors.lastname: Dietel
mesh_terms: D001685:Biological Factors / Q000627:therapeutic use*; D016207:Cytokines; D004355:Drug Stability; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000187:drug effects / Q000502:physiology*; D008222:Lymphokines / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D011994:Recombinant Proteins; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D001685:Biological Factors; D016207:Cytokines; D007370:Interferon Type I; D008222:Lymphokines; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma